Next Phase Newsletter

A tech-driven pharmaceutical company based in the U.S. leverages its AI-powered drug development platform, the firm seeks to acquire promising drug candidates and develop them in-house faster and more efficiently than industry norms. The firm is interested in early clinical-stage therapeutic assets, and its typical deal structures include acquisitions and in-licensing. While equity investments are occasionally possible, the firm prefers to take a majority share and does not typically act as a minority investor. The firm is open to opportunities globally. 
 
The firm is interested in traditional therapeutic assets such as small molecules and biologics, with a primary focus on immunology, dermatology, and orphan diseases. Other indications of interest include CNS, cardiovascular, and metabolic diseases. The firm generally avoids cell therapy and oncology. As for development phases, the earliest the firm will consider is within 12 months of IND, with no limitation on how late the asset is in the clinical stage. 
 
The firm does not have specific requirements for a company’s management team, as the firm aims to take over the asset and typically does not act as a minority investor. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A European life science VC fund manager invests across all healthcare verticals and stages, in products with the potential to address unmet medical needs. The firm invests throughout Europe, with a focus on the Nordics and DACH, and flexibility for 1-2 US investments. Initial investments are typically €7-8 million. 
 
The firm invests across the life science sector, including therapeutics, devices and diagnostics. The firm only invests in products that are subject to medical regulation. The firm will consider any indication or modality. The firm prefers to invest in assets that are at least ready to go into clinical trials. 
 
The firm is a European investor with a focus on companies based in Europe but will consider US investments with a US lead investor. While the firm does not exclude any areas of opportunity, there is a focus on de-risked assets and areas in which the execution and regulatory risk for the asset is reduced. 
 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

An investment management firm is led by partners who have been co-founders / founding executives of successfully exited healthtech companies, with expertise spanning various fields of life sciences. The firm is an active investor in life sciences & healthcare, and is open to all stages of development. Typical investment size is $1-2M for early stage companies, though the size can go up to over $10M in later-stage companies. The firm is open to global opportunities. 
 
The firm invests broadly across therapeutics, medical devices, diagnostics, and digital health, with stronger interests in the first 3 sectors listed. The firm seeks first-in-class / best-in-class technologies that address unmet medical need. In terms of indication, oncology is less of a priority, but is still considered. The firm is open to reviewing both pre-clinical and clinical stage technologies. 
 
The firm seeks to work with companies backed by a committed management team. The firm can act as either a lead/co-lead or co-investor. The firm is capable of getting other family offices involved in forming a syndicate on a deal-by-deal basis. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.